Logo image of ADXS

ADVAXIS INC (ADXS) Stock Fundamental Analysis

NASDAQ:ADXS - Nasdaq - Common Stock

0.155  -0.08 (-35.42%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADXS. ADXS was compared to 562 industry peers in the Biotechnology industry. ADXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADXS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADXS has reported negative net income.
ADXS Yearly Net Income VS EBIT VS OCF VS FCFADXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -37.01%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADXS Yearly ROA, ROE, ROICADXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 -50 -100 -150 -200 -250

1.3 Margins

The Operating Margin and Gross Margin are not available for ADXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -581.85%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADXS Yearly Profit, Operating, Gross MarginsADXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ADXS has been increased compared to 1 year ago.
ADXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADXS Yearly Shares OutstandingADXS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 20M 40M 60M
ADXS Yearly Total Debt VS Total AssetsADXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 50M 100M 150M

2.2 Solvency

ADXS has an Altman-Z score of -9.92. This is a bad value and indicates that ADXS is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for ADXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.92
ROIC/WACCN/A
WACCN/A
ADXS Yearly LT Debt VS Equity VS FCFADXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 7.03 indicates that ADXS has no problem at all paying its short term obligations.
ADXS has a Quick Ratio of 7.03. This indicates that ADXS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 7.03
Quick Ratio 7.03
ADXS Yearly Current Assets VS Current LiabilitesADXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

ADXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.75%, which is quite impressive.
The Revenue has grown by 1198.00% in the past year. This is a very strong growth!
The Revenue for ADXS have been decreasing by -72.51% on average. This is quite bad
EPS 1Y (TTM)58.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)1198%
Revenue growth 3Y-72.51%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ADXS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.00% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.87%
EPS Next 2Y28.29%
EPS Next 3Y18.07%
EPS Next 5Y10%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADXS Yearly Revenue VS EstimatesADXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M
ADXS Yearly EPS VS EstimatesADXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADXS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADXS Price Earnings VS Forward Price EarningsADXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.27
ADXS Per share dataADXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

A more expensive valuation may be justified as ADXS's earnings are expected to grow with 18.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.29%
EPS Next 3Y18.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADXS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVAXIS INC

NASDAQ:ADXS (12/23/2021, 11:39:10 AM)

0.155

-0.08 (-35.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)04-01 2022-04-01/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners2.44%
Ins Owner Change0%
Market Cap22.57M
Analysts82.86
Price Target2.3 (1383.87%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.96
P/FCF N/A
P/OCF N/A
P/B 0.51
P/tB N/A
EV/EBITDA 1.27
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.02
BVpS0.3
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -581.85%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.03
Quick Ratio 7.03
Altman-Z -9.92
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next Y59.87%
EPS Next 2Y28.29%
EPS Next 3Y18.07%
EPS Next 5Y10%
Revenue 1Y (TTM)1198%
Revenue growth 3Y-72.51%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A